Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, early breast cancer in BRCA1/2 variant carriers.

Back to Main Guidelines Page